Latest Articles
Cambridgeshire gym boss takes on daily walk to highlight ‘terrible’ disease - Ely Standard
Cambridgeshire gym boss takes on daily walk to highlight ‘terrible’ disease Ely Standard
Published: March 4, 2026, 7 a.m.
Construction and initial validation of key gene network for progesterone resistance in endometrial cancer based on genome-wide CRISPR screening - Nature
Construction and initial validation of key gene network for progesterone resistance in endometrial cancer based on genome-wide CRISPR screening Nature
Published: March 3, 2026, 10:36 a.m.
Endometriosis Shuswap looking to spread the word about the disease - Castanet
Endometriosis Shuswap looking to spread the word about the disease Castanet
Published: March 3, 2026, 3 a.m.
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - Defense World
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer Defense World
Published: March 2, 2026, 6:50 p.m.
ACOG Releases Updated Clinical Guidance on Endometriosis to Accelerate Diagnosis and Improve Access to... - Medical Dialogues
ACOG Releases Updated Clinical Guidance on Endometriosis to Accelerate Diagnosis and Improve Access to... Medical Dialogues
Published: March 2, 2026, 2:45 p.m.
Center for Endometriosis Care Calls for Greater Disease Support During Endometriosis Awareness Month - PR.com
Center for Endometriosis Care Calls for Greater Disease Support During Endometriosis Awareness Month PR.com
Published: March 2, 2026, 8 a.m.
ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon - TipRanks
ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon TipRanks
Published: Feb. 27, 2026, 7:47 p.m.
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - MarketBeat
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer MarketBeat
Published: Feb. 27, 2026, 4:50 p.m.
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - Yahoo Finance
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer Yahoo Finance
Published: Feb. 27, 2026, 4:47 p.m.
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data - TipRanks
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data TipRanks
Published: Feb. 27, 2026, 3:24 p.m.
Link copied to clipboard!